Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone effects on systemic inflammation in COPD
NCT00175565Phase 4Completed
- Sponsor
- University of British Columbia
- Start
- Jan 2002
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fluticasone propionate nasal spray in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by University of British Columbia. Primary endpoint: Change in serum C-reactive protein at 18 weeks. Started Jan 2002; status: completed.
02
Drugs
fluticasone propionate nasal spray
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00175565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00175565.